Members of the ErbB subfamily of receptor tyrosine kinases are important regulators of normal mammary gland physiology, and aberrations in their signaling have been associated with breast tumorigenesis. Therapeutics targeting epidermal growth factor receptor (EGFR = ErbB1) or ErbB2 in breast cancer have been approved for clinical use. In contrast, relatively little is known about the biological significance of ErbB4 signaling in breast cancer. This review focuses on recent advances in our understanding about the role of ErbB4 in breast carcinogenesis, as well as in the potential clinical relevance of ErbB4 in breast cancer prognostics and therapy. © Springer Science+Business Media, LLC 2008.
CITATION STYLE
Sundvall, M., Iljin, K., Kilpinen, S., Sara, H., Kallioniemi, O. P., & Elenius, K. (2008, June). Role of ErbB4 in breast cancer. Journal of Mammary Gland Biology and Neoplasia. https://doi.org/10.1007/s10911-008-9079-3
Mendeley helps you to discover research relevant for your work.